Explainer
Lymphoma explained: Hodgkin and non-Hodgkin, symptoms and survival
Lymphoma is cancer that begins in cells of the lymph system, part of the immune system; the two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).[1] NCI says Hodgkin lymphoma can often be cured, while the outlook for NHL depends on its specific type.[2] SEER publishes estimates of about 79,320 new US cases of NHL and 8,920 of Hodgkin lymphoma in 2026, with 5-year relative survival of 74.3% and 89.3%.[3][4][5][6]
This page is general information, not medical advice. See a doctor about lumps that do not go away, soaking night sweats or unexplained weight loss.
Lymphoma is cancer that begins in cells of the lymph system, which is part of the immune system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).[1] NCI says Hodgkin lymphoma can often be cured, while the outlook for NHL depends on its specific type.[2] Our immune system explainer covers the cells involved.
Non-Hodgkin lymphoma
Non-Hodgkin lymphomas begin when a B cell or T cell, both types of white blood cell, becomes abnormal and keeps dividing. The abnormal cells can spread to almost any part of the body.[7] Doctors usually do not know why a person gets NHL, but a weakened immune system and certain infections raise the risk.[8]
SEER publishes estimates of about 79,320 new US cases and 19,970 deaths in 2026. NHL is 3.8% of new cancer cases and the eighth leading cause of US cancer death, and it is most often diagnosed at ages 65 to 74.[3] SEER reports 5-year relative survival of 74.3%, based on 2016-2022 data. About 21% of cases are found at stage I, when survival is 87.6%.[5] New cases fell an average of 0.6% a year over 2014-2023, and death rates fell 2.4% a year over 2015-2024.[9]
Hodgkin lymphoma
Hodgkin lymphoma is much less common than NHL, making up 0.4% of new cancers.[3] SEER publishes estimates of about 8,920 new US cases and 1,100 deaths in 2026. It is more common in young adults and men, and it is most often diagnosed at ages 20 to 34.[4] SEER reports 5-year relative survival of 89.3%, based on 2016-2022 data, and death rates fell an average of 3.1% a year over 2015-2024.[6]
Symptoms
Symptoms of NHL can include swollen, painless lymph nodes in the neck, armpits or groin, unexplained weight loss, fever and soaking night sweats. Cough or breathlessness, lasting tiredness and abdominal pain or swelling can also occur.[10] Our cancer warning signs page covers when to get checked.
Diagnosis and treatment
Lymphoma is diagnosed with a physical exam, blood tests, a chest X-ray and a biopsy. Treatments include chemotherapy, radiation, targeted therapy, biological therapy and stem cell transplant. People without symptoms may be monitored instead of treated straight away, an approach called watchful waiting.[11]
In March 2026 the FDA approved nivolumab, a checkpoint inhibitor, with chemotherapy for untreated Hodgkin lymphoma.[12] In December 2025 it approved lisocabtagene maraleucel (Breyanzi) as the first CAR T-cell therapy for marginal zone lymphoma.[13] Our cancer immunotherapy explainer covers these drug classes.
SEER notes that survival statistics are based on large groups and cannot predict what will happen to any one person.[14]
Read next
Leukaemia explained: types, symptoms, survival and treatment
What leukaemia is, how acute and chronic types differ, the four main types, warning signs, how it is diagnosed and treated, and US survival figures.
Questions readers ask
What is the difference between Hodgkin and non-Hodgkin lymphoma?
They are the two main types of lymphoma. NCI says Hodgkin lymphoma can often be cured, while the outlook for non-Hodgkin lymphoma depends on its specific type. Hodgkin lymphoma is less common and most often diagnosed at ages 20 to 34; NHL is most often diagnosed at 65 to 74.[1][2][4][3]
What are the symptoms of lymphoma?
For non-Hodgkin lymphoma, swollen painless lymph nodes in the neck, armpits or groin, unexplained weight loss, fever, soaking night sweats, cough or breathlessness, lasting tiredness and abdominal pain or swelling.[10]
What causes non-Hodgkin lymphoma?
Doctors usually do not know. A weakened immune system and certain infections raise the risk.[8]
How is lymphoma diagnosed?
With a physical exam, blood tests, a chest X-ray and a biopsy.[11]
Does lymphoma always need treatment straight away?
Not always. MedlinePlus says people without symptoms may not need treatment right away and may be monitored instead, an approach called watchful waiting.[11]
Sources
· 14 claims from 4 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Lymphoma is cancer that begins in cells of the lymph system, part of the immune system; the two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). confirmedas of 2026-11-14
- [2]
NCI says Hodgkin lymphoma can often be cured, while the outlook for non-Hodgkin lymphoma depends on its specific type. confirmedas of 2026-11-14
- Lymphoma · National Cancer Institute (NIH) · Primary source · Overview (retrieved 2026-11-14)
- [3]
SEER publishes estimates of about 79,320 new US non-Hodgkin lymphoma cases and 19,970 deaths in 2026; NHL is 3.8% of new cancer cases, the eighth leading cause of US cancer death and most often diagnosed at ages 65 to 74. confirmedas of 2026-11-14
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Statistics at a glance (retrieved 2026-11-14)
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Number of new cases and deaths (retrieved 2026-11-14)
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Deaths (retrieved 2026-11-14)
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · New cases by age (range 65-74) (retrieved 2026-11-14)
- [4]
SEER publishes estimates of about 8,920 new US Hodgkin lymphoma cases and 1,100 deaths in 2026; it makes up 0.4% of new cancers, is more common in young adults and men, and most often diagnosed at ages 20 to 34. confirmedas of 2026-11-14
- Cancer Stat Facts: Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Statistics at a glance (retrieved 2026-11-14)
- Cancer Stat Facts: Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Number of new cases and deaths (retrieved 2026-11-14)
- Cancer Stat Facts: Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Number of new cases and deaths (retrieved 2026-11-14)
- Cancer Stat Facts: Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · New cases by age (range 20-34) (retrieved 2026-11-14)
- [5]
SEER reports 5-year relative survival for non-Hodgkin lymphoma of 74.3% overall (2016-2022 data); 21% of cases are found at stage I, when survival is 87.6%. confirmedas of 2026-11-14
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Statistics at a glance (retrieved 2026-11-14)
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Survival by stage (retrieved 2026-11-14)
- [6]
SEER reports 5-year relative survival for Hodgkin lymphoma of 89.3%, based on 2016-2022 data, and says death rates fell an average of 3.1% a year over 2015-2024. confirmedas of 2026-11-14
- Cancer Stat Facts: Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Statistics at a glance (retrieved 2026-11-14)
- Cancer Stat Facts: Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Changes over time (range 2015-2024) (retrieved 2026-11-14)
- [7]
Non-Hodgkin lymphomas begin when a B cell or T cell, both types of white blood cell, becomes abnormal and keeps dividing; the abnormal cells can spread to almost any part of the body. confirmedas of 2026-11-14
- [8]
Doctors usually do not know why a person gets non-Hodgkin lymphoma; a weakened immune system and certain infections raise the risk. confirmedas of 2026-11-14
- Lymphoma · MedlinePlus, US National Library of Medicine · Primary source · Summary (retrieved 2026-11-14)
- [9]
SEER says age-adjusted NHL incidence fell an average of 0.6% a year over 2014-2023, and death rates fell 2.4% a year over 2015-2024. confirmedas of 2026-11-14
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Changes over time (range 2014-2023) (retrieved 2026-11-14)
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · Changes over time (range 2015-2024) (retrieved 2026-11-14)
- [10]
Symptoms of non-Hodgkin lymphoma can include swollen, painless lymph nodes in the neck, armpits or groin, unexplained weight loss, fever, soaking night sweats, cough or breathlessness, lasting tiredness and abdominal pain or swelling. confirmedas of 2026-11-14
- [11]
Lymphoma is diagnosed with a physical exam, blood tests, a chest X-ray and a biopsy; treatments include chemotherapy, radiation, targeted therapy, biological therapy and stem cell transplant, and people without symptoms may be monitored without immediate treatment. confirmedas of 2026-11-14
- Lymphoma · MedlinePlus, US National Library of Medicine · Primary source · Summary (retrieved 2026-11-14)
- Lymphoma · MedlinePlus, US National Library of Medicine · Primary source · Summary (retrieved 2026-11-14)
- Lymphoma · MedlinePlus, US National Library of Medicine · Primary source · Summary (retrieved 2026-11-14)
- Lymphoma · National Cancer Institute (NIH) · Primary source · Treatment (retrieved 2026-11-14)
- [12]
FDA checkpoint-inhibitor approvals in 2026 included nivolumab with chemotherapy for untreated Hodgkin lymphoma (20 March) and durvalumab with BCG for high-risk non-muscle invasive bladder cancer (28 May). confirmedas of 2026-10-10
- Oncology (Cancer)/Hematologic Malignancies Approval Notifications · US Food and Drug Administration · Primary source (retrieved 2026-10-10)
- [13]
On 4 December 2025 the FDA approved lisocabtagene maraleucel (Breyanzi) as the first CAR T-cell therapy for marginal zone lymphoma; 95.5% of 66 treated patients responded. confirmedas of 2025-12-04
- FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma in the US · US Food and Drug Administration · Primary source · 2025-12-04 (retrieved 2026-10-10)
- [14]
SEER says survival statistics are based on large groups of people and cannot predict exactly what will happen to an individual patient. confirmedas of 2026-11-14
- Cancer Stat Facts: Leukemia · National Cancer Institute SEER Program · Primary source · How many people survive 5 years or more (retrieved 2026-11-14)
- Cancer Stat Facts: Non-Hodgkin Lymphoma · National Cancer Institute SEER Program · Primary source · How many people survive 5 years or more (retrieved 2026-11-14)
- Cancer Stat Facts: Pancreatic Cancer · National Cancer Institute SEER Program · Primary source · How many people survive 5 years or more (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 14, 2026. Next scheduled review: May 28, 2027.
Cite this page
"Lymphoma explained: Hodgkin and non-Hodgkin, symptoms and survival." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/lymphoma-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.